|
US7192584B2
(en)
*
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
CA2441228A1
(en)
*
|
2001-03-23 |
2002-10-03 |
Aphton Corporation |
Combination treatment of pancreatic cancer
|
|
US20090191232A1
(en)
*
|
2001-05-04 |
2009-07-30 |
Gevas Philip C |
Combination therapy for the treatment of tumors
|
|
JP2004536835A
(ja)
*
|
2001-07-09 |
2004-12-09 |
アフトン コーポレーション |
肝臓、肺および食道の癌性ならびに前癌性状態の治療および防止
|
|
US20060165675A1
(en)
*
|
2002-08-02 |
2006-07-27 |
Richman-Eisenstat Janice Beth |
Modulation of mesenchymal cells via iga-receptors
|
|
US7235376B2
(en)
*
|
2003-03-28 |
2007-06-26 |
Receptor Biologix, Inc. |
Gastrin hormone immunoassays
|
|
US20060020119A1
(en)
*
|
2004-03-29 |
2006-01-26 |
Stephen Grimes |
Monoclonal antibodies to gastrin hormone
|
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
EP1570858A1
(en)
*
|
2004-03-05 |
2005-09-07 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Monovalent ligand of the FCalphaRi receptor as an anti-inflammatory agent
|
|
EP2567974A3
(en)
|
2004-09-22 |
2013-05-22 |
Cancer Advances, Inc., |
Monoclonal antibodies to progastrin
|
|
CA2606081C
(en)
*
|
2005-04-26 |
2013-09-17 |
Markus M. Heiss |
Combination of the application of antibodies for immunostimulation together with glucocorticoids
|
|
AU2006272555B2
(en)
|
2005-07-25 |
2012-03-08 |
Aptevo Research And Development Llc |
B-cell reduction using CD37-specific and CD20-specific binding molecules
|
|
CN105837690A
(zh)
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
具有效应功能的单链多价结合蛋白
|
|
WO2009025364A1
(ja)
|
2007-08-23 |
2009-02-26 |
Mitsubishi Kagaku Iatron, Inc. |
非特異反応抑制剤
|
|
NZ603059A
(en)
|
2008-04-11 |
2014-07-25 |
Emergent Product Dev Seattle |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
|
EP2127666A1
(en)
*
|
2008-05-28 |
2009-12-02 |
Drug Discovery Factory B.V. |
Method for the treatment or prophylaxis of chronic inflammatory diseases
|
|
WO2011088219A2
(en)
*
|
2010-01-13 |
2011-07-21 |
The Uab Research Foundation |
Therapeutics and processes for treatment of immune disorders
|
|
JP6002659B2
(ja)
|
2010-04-13 |
2016-10-05 |
セルデックス・セラピューティクス・インコーポレイテッド |
ヒトｃｄ２７に結合する抗体およびその使用
|
|
US9517257B2
(en)
|
2010-08-10 |
2016-12-13 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Erythrocyte-binding therapeutics
|
|
US9850296B2
(en)
|
2010-08-10 |
2017-12-26 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Erythrocyte-binding therapeutics
|
|
AU2011289579B2
(en)
|
2010-08-10 |
2016-11-17 |
Ecole Polytechnique Federale De Lausanne |
Erythrocyte-binding therapeutics
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
EP2465536A1
(en)
*
|
2010-12-14 |
2012-06-20 |
CSL Behring AG |
CD89 activation in therapy
|
|
AU2013216863B2
(en)
*
|
2012-02-10 |
2018-09-06 |
Seagen Inc. |
Detection and treatment of CD30+ cancers
|
|
CN104254542A
(zh)
|
2012-03-09 |
2014-12-31 |
瑞士杰特贝林生物制品有限公司 |
包含分泌-样免疫球蛋白的组合物
|
|
EP2636684A1
(en)
|
2012-03-09 |
2013-09-11 |
CSL Behring AG |
Prevention of infection
|
|
EP2636681A1
(en)
|
2012-03-09 |
2013-09-11 |
CSL Behring AG |
Process for enriching IgA
|
|
US10946079B2
(en)
|
2014-02-21 |
2021-03-16 |
Ecole Polytechnique Federale De Lausanne |
Glycotargeting therapeutics
|
|
US10953101B2
(en)
|
2014-02-21 |
2021-03-23 |
École Polytechnique Fédérale De Lausanne (Epfl) |
Glycotargeting therapeutics
|
|
US10046056B2
(en)
|
2014-02-21 |
2018-08-14 |
École Polytechnique Fédérale De Lausanne (Epfl) |
Glycotargeting therapeutics
|
|
CA2946064C
(en)
|
2014-02-21 |
2023-09-26 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Glycotargeting therapeutics
|
|
US10668147B2
(en)
*
|
2015-03-25 |
2020-06-02 |
Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. |
Anti-CD89 cytotoxic complex
|
|
JOP20160131B1
(ar)
|
2015-06-26 |
2022-03-14 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
|
HK1251480A1
(zh)
|
2015-09-21 |
2019-02-01 |
Aptevo Research And Development Llc |
Cd3结合多肽
|
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
|
US12188935B2
(en)
|
2016-09-30 |
2025-01-07 |
Centre National De La Recherche Scientifique |
Method for the evaluation of antiretroviral therapy (ART) effectiveness in HIV-1 CD4+CD89+ cellular reservoirs
|
|
EP3519822B1
(fr)
*
|
2016-09-30 |
2021-05-12 |
Centre National De La Recherche Scientifique |
Marqueurs cellulaires
|
|
CA3045944A1
(en)
|
2016-12-07 |
2018-06-14 |
Progenity, Inc. |
Gastrointestinal tract detection methods, devices and systems
|
|
KR102616666B1
(ko)
|
2016-12-23 |
2023-12-27 |
노파르티스 아게 |
인자 xi 항체 및 사용 방법
|
|
CA3054632A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
|
US12150978B2
(en)
|
2017-06-15 |
2024-11-26 |
Cancer Advances Inc. |
Compositions and methods for preventing tumors and cancer
|
|
IL271427B2
(en)
|
2017-06-15 |
2025-08-01 |
Cancer Advances Inc |
Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
|
|
EP3638296A1
(en)
|
2017-06-16 |
2020-04-22 |
The University Of Chicago |
Compositions and methods for inducing immune tolerance
|
|
JP7009517B2
(ja)
|
2017-06-21 |
2022-01-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体
|
|
KR20210011919A
(ko)
|
2018-04-17 |
2021-02-02 |
셀덱스 쎄라퓨틱스, 인크. |
항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물
|
|
EP3790577A4
(en)
|
2018-05-09 |
2022-04-27 |
The University of Chicago |
COMPOSITIONS AND METHODS RELATED TO IMMUNTOLERANCE
|
|
US20230041197A1
(en)
|
2018-06-20 |
2023-02-09 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
|
US12227565B2
(en)
|
2018-06-20 |
2025-02-18 |
Biora Therapeutics, Inc. |
Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
|
|
CN113348011B
(zh)
|
2018-11-19 |
2023-04-18 |
比奥拉治疗股份有限公司 |
用生物治疗剂治疗疾病的方法和装置
|
|
US12703762B2
(en)
|
2018-12-18 |
2026-08-11 |
Novartis Ag |
Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
|
|
CN121197633A
(zh)
|
2019-12-13 |
2025-12-26 |
比特比德科有限责任公司 |
用于将治疗剂递送至胃肠道的可摄取装置
|
|
MX2022013085A
(es)
*
|
2020-04-21 |
2023-01-11 |
Jjp Biologics Sp Z O O |
Anticuerpos cd89 anti-humanos humanizados y usos de los mismos.
|
|
EP4225792A1
(en)
|
2020-10-08 |
2023-08-16 |
Affimed GmbH |
Trispecific binders
|
|
KR102766045B1
(ko)
*
|
2020-11-06 |
2025-02-10 |
고려대학교 산학협력단 |
Fc 알파 수용체 결합력이 향상된 항체
|
|
KR102853685B1
(ko)
*
|
2020-11-06 |
2025-09-01 |
고려대학교 산학협력단 |
Fc 알파 수용체 결합력이 증진된 항체
|
|
KR102855679B1
(ko)
*
|
2020-11-06 |
2025-09-04 |
고려대학교 산학협력단 |
Fc 알파 수용체 결합 항체
|
|
WO2022098084A1
(ko)
*
|
2020-11-06 |
2022-05-12 |
고려대학교 산학협력단 |
Fc 알파 수용체 결합 항체
|
|
JP2024529381A
(ja)
|
2021-07-30 |
2024-08-06 |
アフィメド ゲーエムベーハー |
デュプレックスボディ
|
|
CN121263441A
(zh)
|
2023-04-19 |
2026-01-02 |
森特萨制药(英国)有限公司 |
可活化的双特异性抗cd89和抗pd-l1蛋白质及其用途
|
|
CN116874601A
(zh)
*
|
2023-07-11 |
2023-10-13 |
长春博迅生物技术有限责任公司 |
分泌抗人P1血型IgM型单抗的杂交瘤细胞株及应用
|
|
CN117890576A
(zh)
*
|
2023-12-12 |
2024-04-16 |
深圳市陆为生物技术有限公司 |
一种检测CD89-IgA免疫复合物的试剂、方法及其应用
|
|
WO2025218725A1
(zh)
*
|
2024-04-18 |
2025-10-23 |
徕特康(苏州)生物制药有限公司 |
靶向cd20和cd89的髓细胞衔接子抗体及其用途
|
|
TW202607041A
(zh)
*
|
2024-06-27 |
2026-02-16 |
大陸商無錫徠特康生物科技有限公司 |
靶向ｉｌｔ７和ｃｄ８９的髓細胞銜接子抗體及其用途
|